EP0951296A1 - NOVEL FtsL - Google Patents
NOVEL FtsLInfo
- Publication number
- EP0951296A1 EP0951296A1 EP97937305A EP97937305A EP0951296A1 EP 0951296 A1 EP0951296 A1 EP 0951296A1 EP 97937305 A EP97937305 A EP 97937305A EP 97937305 A EP97937305 A EP 97937305A EP 0951296 A1 EP0951296 A1 EP 0951296A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- polynucleotide
- ftsl
- compnsmg
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 183
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 178
- 229920001184 polypeptide Polymers 0.000 claims abstract description 175
- 238000000034 method Methods 0.000 claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 102000040430 polynucleotide Human genes 0.000 claims description 128
- 108091033319 polynucleotide Proteins 0.000 claims description 128
- 239000002157 polynucleotide Substances 0.000 claims description 128
- 108090000623 proteins and genes Proteins 0.000 claims description 77
- 108020004414 DNA Proteins 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 239000002253 acid Substances 0.000 claims description 30
- 241000191967 Staphylococcus aureus Species 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 239000005557 antagonist Substances 0.000 claims description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000003993 interaction Effects 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 238000010188 recombinant method Methods 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 56
- 102000004169 proteins and genes Human genes 0.000 description 56
- 208000015181 infectious disease Diseases 0.000 description 24
- 230000027455 binding Effects 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 239000000556 agonist Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 206010000269 abscess Diseases 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 206010048038 Wound infection Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 206010031252 Osteomyelitis Diseases 0.000 description 5
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 206010014665 endocarditis Diseases 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000004020 Brain Abscess Diseases 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010014568 Empyema Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 206010021531 Impetigo Diseases 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 201000002481 Myositis Diseases 0.000 description 4
- 206010033078 Otitis media Diseases 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 206010044248 Toxic shock syndrome Diseases 0.000 description 4
- 206010044302 Tracheitis Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 208000013086 acute epiglottitis Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 206010014801 endophthalmitis Diseases 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 208000001606 epiglottitis Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 229920000140 heteropolymer Polymers 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 201000007119 infective endocarditis Diseases 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 201000003453 lung abscess Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010043778 thyroiditis Diseases 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 208000031729 Bacteremia Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 108091092356 cellular DNA Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000010399 physical interaction Effects 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 2
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 2
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- XTMZYFMTYJNABC-ZLUOBGJFSA-N Asn-Ser-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N XTMZYFMTYJNABC-ZLUOBGJFSA-N 0.000 description 2
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- OMOZPGCHVWOXHN-BQBZGAKWSA-N Gly-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)CN OMOZPGCHVWOXHN-BQBZGAKWSA-N 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 2
- RIJCHEVHFWMDKD-SRVKXCTJSA-N Lys-Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RIJCHEVHFWMDKD-SRVKXCTJSA-N 0.000 description 2
- IKXQOBUBZSOWDY-AVGNSLFASA-N Lys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N IKXQOBUBZSOWDY-AVGNSLFASA-N 0.000 description 2
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 2
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 2
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 2
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 2
- CKHWEVXPLJBEOZ-VQVTYTSYSA-N Thr-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O CKHWEVXPLJBEOZ-VQVTYTSYSA-N 0.000 description 2
- SLCSPPCQWUHPPO-JYJNAYRXSA-N Tyr-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SLCSPPCQWUHPPO-JYJNAYRXSA-N 0.000 description 2
- OFHKXNKJXURPSY-ULQDDVLXSA-N Tyr-Met-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O OFHKXNKJXURPSY-ULQDDVLXSA-N 0.000 description 2
- MIAZWUMFUURQNP-YDHLFZDLSA-N Val-Tyr-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N MIAZWUMFUURQNP-YDHLFZDLSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- -1 e g Substances 0.000 description 2
- 101150071760 ftsL gene Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Chemical group 0.000 description 2
- 239000002184 metal Chemical group 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001551 toxigenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- GDTHVMAIBQVUMV-UHFFFAOYSA-N 2-oxopentanal Chemical compound CCCC(=O)C=O GDTHVMAIBQVUMV-UHFFFAOYSA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 1
- XSTZMVAYYCJTNR-DCAQKATOSA-N Ala-Met-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XSTZMVAYYCJTNR-DCAQKATOSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- AMIQZQAAYGYKOP-FXQIFTODSA-N Arg-Ser-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O AMIQZQAAYGYKOP-FXQIFTODSA-N 0.000 description 1
- OPEPUCYIGFEGSW-WDSKDSINSA-N Asn-Gly-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OPEPUCYIGFEGSW-WDSKDSINSA-N 0.000 description 1
- BLQBMRNMBAYREH-UWJYBYFXSA-N Asp-Ala-Tyr Chemical compound N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O BLQBMRNMBAYREH-UWJYBYFXSA-N 0.000 description 1
- RDRMWJBLOSRRAW-BYULHYEWSA-N Asp-Asn-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O RDRMWJBLOSRRAW-BYULHYEWSA-N 0.000 description 1
- MJJIHRWNWSQTOI-VEVYYDQMSA-N Asp-Thr-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MJJIHRWNWSQTOI-VEVYYDQMSA-N 0.000 description 1
- BJDHEININLSZOT-KKUMJFAQSA-N Asp-Tyr-Lys Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(O)=O BJDHEININLSZOT-KKUMJFAQSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017916 Gastroenteritis staphylococcal Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 1
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 description 1
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 241000271915 Hydrophis Species 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- VVQJGYPTIYOFBR-IHRRRGAJSA-N Leu-Lys-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)O)N VVQJGYPTIYOFBR-IHRRRGAJSA-N 0.000 description 1
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 1
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
- QCZYYEFXOBKCNQ-STQMWFEESA-N Lys-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCZYYEFXOBKCNQ-STQMWFEESA-N 0.000 description 1
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 1
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- DTICLBJHRYSJLH-GUBZILKMSA-N Met-Ala-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O DTICLBJHRYSJLH-GUBZILKMSA-N 0.000 description 1
- UZVWDRPUTHXQAM-FXQIFTODSA-N Met-Asp-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O UZVWDRPUTHXQAM-FXQIFTODSA-N 0.000 description 1
- KAKJTZWHIUWTTD-VQVTYTSYSA-N Met-Thr Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)O)C([O-])=O KAKJTZWHIUWTTD-VQVTYTSYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710190786 PI protein Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- CWZUFLWPEFHWEI-IHRRRGAJSA-N Pro-Tyr-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O CWZUFLWPEFHWEI-IHRRRGAJSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000021326 Ritter disease Diseases 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
- 241000966334 Simias Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 208000008582 Staphylococcal Food Poisoning Diseases 0.000 description 1
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- WFAUDCSNCWJJAA-KXNHARMFSA-N Thr-Lys-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(O)=O WFAUDCSNCWJJAA-KXNHARMFSA-N 0.000 description 1
- 206010044250 Toxic shock syndrome staphylococcal Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- MNMYOSZWCKYEDI-JRQIVUDYSA-N Tyr-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MNMYOSZWCKYEDI-JRQIVUDYSA-N 0.000 description 1
- AOLHUMAVONBBEZ-STQMWFEESA-N Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AOLHUMAVONBBEZ-STQMWFEESA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- VMRFIKXKOFNMHW-GUBZILKMSA-N Val-Arg-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N VMRFIKXKOFNMHW-GUBZILKMSA-N 0.000 description 1
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 1
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000017756 staphylococcal toxic-shock syndrome Diseases 0.000 description 1
- 201000002190 staphyloenterotoxemia Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses.
- the invention relates to novel polynucleondes and polypeptides of the penicillin binding protein family, hereinafter referred to as "FtsL”.
- Staphylococcal genes and gene products are particularly preferred to employ Staphylococcal genes and gene products as targets for the development of antibiotics.
- the Staphylococci make up a medically important genera of microbes. T ey are known to produce two types of disease, invasive and toxigenic. Invasive infections are characte ⁇ zed generally by abscess formation effecting both skin surfaces and deep tissues. S. aureus is the second leading cause of bacteremia in cancer patients Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacte ⁇ al endocarditis are also relatively common. There are at least three clinical conditions resulting from the toxigenic properties of Staphylococci. The manifestation of these diseases result from the actions of exotoxms as opposed to tissue invasion and bacteremia. These conditions include: Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome
- Staphylococcus aureus infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate Staphylococcus aureus strains which are resistant to some or all of the standard antibiotics. This has created a demand for both new anti-microbial agents and diagnostic tests for this organism.
- FtsL is a membrane bound protein involved in bactenal cell division. FtsL is essential for cell growth and division. An ftsL null mutation results in inhibition of cell division, the formation of long, non-septate filaments, and ultimately cessation of growth and lysis (Guzman, L-M., Barondess, J. J., and Beckwith, J. (1992) J. Bacte ⁇ ol 174 : 7716-7728)
- Penicilhn-bmdmg protein 3 a membrane protein specifically required during septation (Ishmo, F.,
- FtsL is also a cytoplasmic membrane protein with a cytoplasmic N-terminus, a membrane-spanning segment, and a penplasmic carboxy terminus.
- polypeptides of the invention have amino acid sequence homology to a known Bacillus subtihs FtsL protein.
- the polynucleotide comp ⁇ ses a region encodmg FtsL polypeptides comprising the sequence set out in Table 1 [SEQ LD NO 1] which includes a full length gene, or a vanant thereof.
- an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Staphylococcus aureus WCUH 29 strain contained in the deposited strain
- a further aspect of the invention there are provided isolated nucleic acid molecules encoding FtsL, particularly Staphylococcus aureus FtsL, including mRNAs, cDNAs, genomic
- DNAs Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful va ⁇ ants thereof, and compositions comp ⁇ smg the same.
- a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization
- particularly preferred embodiments of the invention are naturally occurring allehc vanants of FtsL and polypeptides encoded thereby
- FtsL novel polypeptides of Staphylococcus aureus referred to herein as FtsL as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful vanants thereof, and composmons comp ⁇ sing the same
- va ⁇ ants of FtsL polypeptide encoded by naturally occurring alleles of the FtsL gene are va ⁇ ants of FtsL polypeptide encoded by naturally occurring alleles of the FtsL gene.
- FtsL polypeptides useful as antibactenal agents, including, for example, antibodies
- products, compositions and methods for assessing FtsL expression treating disease, for example, disease, such as, infections of the upper respiratory tract (e g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g , infective endocarditis), gastrointestinal (e.g , secretory diarrhoea, splenic absces, retrope ⁇ toneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepha ⁇ tis, conjunctivitis, keratiti
- atitis media e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis
- lower respiratory e.g., empyema, lung
- polynucleotides that hyb ⁇ dize to FtsL polynucleotide sequences, particularly under stnngent conditions.
- methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention comp ⁇ smg: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal m response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determinmg whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polynucleotide.
- FtsL agonists and antagonists preferably bacte ⁇ ostatic or bacte ⁇ ocidal agonists and antagonists.
- compositions compnsing a FtsL polynucleotide or a FtsL polypeptide for administration to a cell or to a multicellular organism preferably bacte ⁇ ostatic or bacte ⁇ ocidal agonists and antagonists.
- “Host cell” is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.
- Identity is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences
- identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between stnngs of such sequences.
- Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and simila ⁇ ty are codified m publicly available computer programs Preferred computer program methods to determine identity and similanty between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., J. Molec. Biol. 215.
- BLAST X program is publicly available from NCBI and other sources ⁇ BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894, Altschul, S , et al , J Mol Biol 215 403-410 (1990)
- a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO 1.
- a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides m the reference sequence may be inserted into the reference sequence
- These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides m the reference sequence or in one or more contiguous groups within the reference sequence.
- a polypeptide having an ammo acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO 2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ LD NO 2
- up to 5% of the ammo acid residues in the reference sequence may be deleted or substituted with another ammo acid, or a number of amino acids up to 5% of the total ammo acid residues m the reference sequence may be inserted into the reference sequence.
- These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference ammo acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or m one or more contiguous groups within the reference sequence
- Isolated means altered “by the hand of man” from its natural state, i e , if it occurs m nature, it has been changed or removed from its o ⁇ ginal environment, or both.
- a polynucleonde or a polypeptide naturally present in a living organism is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting mate ⁇ als of its natural state is “isolated" as the term is employed herein
- Polynucleot ⁇ de(s) generally refers to any poly ⁇ bonucleotide or polydeox ⁇ bonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- Polynucleot ⁇ de(s) include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and tnple-stranded regions, single- and double- stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybnd molecules compnsmg DNA and RNA that may be single-stranded or, more typically, double-stranded, or tnple-stranded regions, or a mixture of single- and double-stranded regions.
- polynucleotide refers to tnple-stranded regions comp ⁇ smg RNA or DNA or both RNA and DNA.
- the strands m such regions may be from the same molecule or from different molecules.
- the regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules.
- One of the molecules of a t ⁇ ple-helical region often is an ohgonucleotide.
- polynucleot ⁇ de(s) also includes DNAs or RNAs as descnbed above that contain one or more modified bases
- DNAs or RNAs with backbones modified for stability or for other reasons are “polynucleot ⁇ de(s)” as that term is intended herein
- DNAs or RNAs compnsmg unusual bases, such as inosine, or modified bases, such as t ⁇ tylated bases, to name just two examples are polynucleotides as the term is used herein. It will be appreciated that a great vanety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art.
- polynucleot ⁇ de(s) as it is employed herein embraces such chemically, enzymatically or metabolicaily modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characte ⁇ stic of viruses and cells, including, for example, simple and complex cells. "Polynucleot ⁇ de(s)” also embraces short polynucleotides often referred to as ohgonucleot ⁇ de(s).
- Polypept ⁇ de(s) refers to any peptide or protein compnsmg two or more ammo acids joined to each other by peptide bonds or modified peptide bonds. "Polypept ⁇ de(s)” refers to both short chains, commonly referred to as peptides, o gopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain ammo acids other than the 20 gene encoded amino acids. “Polypept ⁇ de(s)” include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques.
- Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide de ⁇ vative, covalent attachment of a lipid or lipid de ⁇ vative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, lodination, methylation, mynstoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP- ⁇
- Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.
- Variant(s) is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential prope ⁇ ies.
- a typical vanant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the vanant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in ammo acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
- a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
- a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
- a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
- a variant of a polynucleotide or polypeptide may be a naturally occumng such as an allelic variant, or it may be a variant that is not known to occur naturally. Non- naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.
- the invention relates to novel FtsL polypeptides and polynucleotides as described in greater detail below.
- the invention relates to polypeptides and polynucleotides of a novel FtsL of Staphylococcus aureus, which is related by ammo acid sequence homology to Bacillus subtilis FtsL polypeptide.
- the invention relates especially to FtsL having the nucleotide and ammo acid sequences set out in Table 1 [SEQ LD NO: 1] and Table 1 [SEQ ID NO: 2] respectively, and to the FtsL nucleotide sequences of the DNA in the deposited strain and amino acid sequences encoded thereby.
- a deposit containing a Staphylococcus aureus WCUH 29 strain has been deposited with the National Collections of Industnal and Ma ⁇ ne Bacte ⁇ a Ltd. (herein "NCIMB"), 23 St Machar Dnve, Aberdeen AB2 1RY, Scotland on 11 September 1995 and assigned NCIMB Deposit No 40771, and is referred to as Staphylococcus aureus WCUH29 on deposit
- the Staphylococcus aureus strain deposit is referred to herein as "the deposited strain” or as "the DNA of the deposited strain.”
- the deposited strain contains the full length FtsL gene.
- the sequence of the polynucleotides contained in the deposited strain, as well as the ammo acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any descnption of sequences herein.
- the deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The strain will be irrevocably and without restnction or condition released to the public upon the issuance of a patent
- the deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. ⁇ 112
- a license may be required to make, use or sell the deposited strain, and compounds de ⁇ ved therefrom, and no such license is hereby granted Polypeptides
- polypeptides of the invention include the polypeptide of Table 1 [SEQ ID NO 2] (m particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of FtsL, and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ED NOS:2 and 4] or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NOS.2 and 4], and more preferably at least 90% simila ⁇ ty (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NOS.2 and 4] and still more preferably at least 95% simila ⁇ ty (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ED NOS:2 and 4] and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 ammo acids and more preferably at least 50 amino acids
- the invention also includes polypeptides of the formula set forth in Table 1 (D) [SEQ LD
- X is hydrogen
- Y is hydrogen or a metal
- R ⁇ and R2 is any ammo acid residue
- n is an integer between 1 and
- Any stretch of ammo acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.
- a fragment is a vanant polypeptide having an ammo acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides
- FtsL polypeptides fragments may be "free-standing,” or comp ⁇ sed within a larger polypeptide of which they form a part or region, most preferably as a single continuous region, a single larger polypeptide.
- Preferred fragments include, for example, truncation polypeptides having a portion of an ammo acid sequence of Table 1 [SEQ ID NOS:2 and 4], or of va ⁇ ants thereof, such as a continuous senes of residues that includes the ammo terminus, or a continuous senes of residues that includes the carboxyl terminus.
- Degradation forms of the polypeptides of the invention in a host cell, particularly a Staphylococcus aureus are also preferred.
- fragments characte ⁇ zed by structural or functional attributes such as fragments that compnse alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn- forming regions, coil and coil-forming regions, hydrophi c regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.
- biologically active fragments which are those fragments that mediate activities of FtsL, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigenic or lmmunogenic in an animal, especially in a human. Particularly preferred are fragments compnsmg receptors or domains of enzymes that confer a function essential for viability of Staphylococcus aureus or the ability to initiate, or maintain cause disease in an individual, particularly a human.
- Va ⁇ ants that are fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these vanants may be employed as intermediates for producing the full-length polypeptides of the invention.
- Another aspect of the invention relates to isolated polynucleotides, including the full length gene, that encode the FtsL polypeptide having a deduced amino acid sequence of Table 1 [SEQ ID NOS:2 and 4] and polynucleotides closely related thereto and va ⁇ ants thereof.
- Table 1 [SEQ ID NOS:2 and 4]
- polynucleotides closely related thereto and va ⁇ ants thereof Using the information provided herein, such as a polynucleotide sequence set out m Table
- a polynucleotide of the invention encoding FtsL polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacte ⁇ a using Staphylococcus aureus WCUH 29 cells as starting matenal, followed by obtaining a full length clone.
- standard cloning and screening methods such as those for cloning and sequencing chromosomal DNA fragments from bacte ⁇ a using Staphylococcus aureus WCUH 29 cells as starting matenal, followed by obtaining a full length clone.
- a polynucleotide sequence of the invention such as a sequence given in Table 1 [SEQ ID NOS.
- a library of clones of chromosomal DNA of Staphylococcus aureus WCUH 29 in E coli or some other suitable host is probed with a radiolabeled ohgonucleotide, preferably a 17-mer or longer, derived from a partial sequence.
- Clones carrying DNA identical to that of the probe can then be distinguished using stnngent conditions.
- sequencing primers designed from the ongmal sequence it is then possible to extend the sequence m both directions to determine the full gene sequence. Conveniently, such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone.
- the DNA sequence set out m Table 1 [SEQ ED NOS:l] contains an open reading frame encoding a protein having about the number of ammo acid residues set forth in Table 1 [SEQ ID NO:2] with a deduced molecular weight that can be calculated using ammo acid residue molecular weight values well known in the art.
- the polynucleotide of SEQ D NO. 1, between nucleotide number 1 through number 399 encodes the polypeptide of SEQ ED NO:2
- FtsL of the invention is structurally related to other proteins of the penicillin binding protein family, as shown by the results of sequencing the DNA encoding FtsL of the deposited strain.
- the protein exhibits greatest homology to Bacillus subtilis FtsL protein among known
- the invention provides a polynucleotide sequence identical over its entire length to the coding sequence in Table 1 [SEQ ID NO 1] Also provided by the invention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment in reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence
- the polynucleotide may also contain non-coding sequences, including for example, but not limited to non-codmg 5' and 3' sequences, such as the transcnbed, non-translated sequences, termination signals, ⁇ bosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional coding sequence which encode additional ammo acids
- a marker sequence that facilitates punfication of the fused polypeptide can be encoded
- the marker sequence is a hexa-histidine
- Polynucleotides of the invention also include, but are not limited to, polynucleotides compnsmg a structural gene and its naturally associated sequences that control gene expression
- a preferred embodiment of the invention is a polynucleotide of compnsmg nucleotide 1 to 399 set forth in SEQ ED NO: 1 of Table 1 which encode the FtsL polypeptide
- the invention also includes polynucleotides of the formula set forth in Table 1 (C)[SEQ ED NO 1] wherein, at the 5' end of the molecule, X is hydrogen, and at the 3 1 end of the molecule, Y is hydrogen or a metal, Rj and R2 is any nucleic acid residue, and n is an mteger between 1 and 1000. Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer
- polynucleotide encoding a polypeptide encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bactenal polypeptide and more particularly a polypeptide of the Staphylococcus aureus FtsL having the ammo acid sequence set out in Table 1 [SEQ ED NO.2]
- the term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the
- polypeptide for example, interrupted by integrated phage or an insertion sequence or editing
- additional regions that also may contain coding and/or non-coding sequences
- the invention further relates to va ⁇ ants of the polynucleotides descnbed herein that encode for vanants of the polypeptide having the deduced ammo acid sequence of Table 1 [SEQ ED NO.2]. Vanants that are fragments of the polynucleotides of the invention may be used to synthesize full-length polynucleotides of the invention.
- polynucleotides encoding FtsL vanants that have the am o acid sequence of FtsL polypeptide of Table 1 [SEQ ED NO 2] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no ammo acid residues are substituted, deleted or added, in any combination.
- silent substitutions, additions and deletions that do not alter the properties and activities of FtsL.
- polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding FtsL polypeptide having an amino acid sequence set out m Table 1 [SEQ ID NOS:2 and 4], and polynucleotides that are complementary to such polynucleotides.
- polynucleotides that compnse a region that is at least 80% identical over its entire length to a polynucleotide encoding FtsL polypeptide of the deposited strain and polynucleotides complementary thereto
- polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred.
- those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred
- Preferred embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Table 1 [SEQ ED NO:l],
- the invention further relates to polynucleotides that hybndize to the herem above- descnbed sequences.
- the invention especially relates to polynucleotides that hybndize under st ⁇ ngent conditions to the herein above-descnbed polynucleotides.
- st ⁇ ngent conditions and “stnngent hyb ⁇ dization conditions” mean hyb ⁇ dization will occur only if there is at least 95% and preferably at least 97% identity between the sequences
- An example of st ⁇ ngent hyb ⁇ dization conditions is overnight incubation at 42°C in a solution compnsmg 50% formamide, 5x SSC (150mM NaCl, 15mM tnsodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hyb ⁇ dization support in 0 lx SSC at about 65°C Hybndization and wash conditions are well known and exemplified in Sambrook, et al., Molecular Cloning A Laboratory Manual, Second Edition, Cold Spnng Harbor, N Y., (19
- the invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropnate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:l or SEQ ID NO.3 under st ⁇ ngent hyb ⁇ dization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:l or a fragment thereof; and isolating said DNA sequence.
- Fragments useful for obtaining such a polynucleotide include, for example, probes and pnmers descnbed elsewhere herein.
- polynucleotide assays of the invention may be used as a hybndization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding FtsL and to isolate cDNA and genomic clones of other genes that have a high sequence simila ⁇ ty to the FtsL gene
- probes generally will compnse at least 15 bases
- such probes will have at least 30 bases and may have at least 50 bases.
- Particularly preferred probes will have at least 30 bases and will have 50 bases or less.
- the coding region of the FtsL gene may be isolated by screening using the DNA sequence provided in SEQ ED NO: 1 to synthesize an oligonucleotide probe.
- a labeled ohgonucleotide having a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hyb ⁇ dizes to.
- polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and matenals for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to polynucleotide assays
- Polynucleotides of the invention that are o gonucleotides de ⁇ ved from the sequences of SEQ ID NOS: 1 and/or 2 may be used in the processes herein as descnbed, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are
- the invention also provides polynucleotides that may encode a polypeptide that is the mature protein plus additional ammo or carboxyl-terminal amino acids, or amino acids intenor to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance).
- Such sequences may play a role m processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things
- the additional amino acids may be processed away from the mature protein by cellular enzymes.
- a precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide When prosequences are removed such inactive precursors generally are activated Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.
- a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotem, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed du ⁇ ng processing steps that produce active and mature forms of the polypeptide
- the invention also relates to vectors that comp ⁇ se a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.
- Cell-free translation systems can also be employed to produce such proteins using RNAs de ⁇ ved from the DNA constructs of the invention.
- host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention.
- Introduction of a polynucleotide mto the host cell can be effected by methods descnbed in many standard laboratory manuals, such as Davis et al , BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al., MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed., Cold
- encoding for polypeptides of the invention include, among others, chromosomal, episomal and virus-denved vectors,
- the expression system constructs may contain control regions that regulate as well as engender expression
- any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard.
- the appropnate DNA sequence may be inserted into the expression system by any of a vanety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, (supra).
- appropnate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
- Polypeptides of the invention can be recovered and pu ⁇ fied from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid
- t l chromatography is employed for pu ⁇ fication.
- Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured dunng isolation and or punfication.
- Diagnostic Assays This invention is also related to the use of the FtsL polynucleotides of the invention for use as diagnostic reagents. Detection of FtsL in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease.
- Eukaryotes particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism compnsmg the FtsL gene may be detected at the nucleic acid level by a vanety of techniques.
- Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification technique p ⁇ or to analysis. RNA or cDNA may also be used in the same ways. Using amplification, charactenzation of the species and strain of prokaryote present in an individual, may be made by an analysis of the genotype of the prokaryote gene.
- Deletions and insertions can be detected by a change in size of the amplified product m compa ⁇ son to the genotype of a reference sequence
- Point mutations can be identified by hyb ⁇ dizing amplified DNA to labeled FtsL polynucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denatunng agents, or by direct DNA sequencing. See, e.g , Myers et al., Science, 230 1242 (1985).
- Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and SI protection or a chemical cleavage method. See, e.g , Cotton et al., Proc Natl. Acad. Sci., USA, 85. 4397-4401 (1985).
- RNA or cDNA may also be detected at the DNA level by a vanety of techniques, to allow for serotypmg, for example.
- RT-PCR can be used to detect mutations. It is particularly preferred to used RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan.
- RNA or cDNA may also be detected at the DNA level by a vanety of techniques, to allow for serotypmg, for example.
- RT-PCR can be used to detect mutations. It is particularly preferred to used RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan.
- PCR pnmers complementary to a nucleic acid encoding FtsL can be used to identify and analyze mutations.
- the invention further provides these pnmers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end.
- These pnmers may be used for, among other things, amplifying FtsL DNA isolated from a sample derived from an individual.
- the pnmers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to vanous techniques for elucidation of the DNA sequence. In this way, mutations m the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent.
- the invention further provides a process for diagnosing, disease, preferably bactenal infections, more preferably infections by Staphylococcus aureus, and most preferably disease, such as, infections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory diarrhoea, splenic absces, retropentoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital celluhtis, darcryocystitis), kidney and urinary tract (e.g., epididymitis, intrarenal and penneph ⁇ c absces
- Increased or decreased expression of FtsL polynucleotide can be measured using any on of the methods well known in the art for the quantation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hyb ⁇ dization methods.
- a diagnostic assay in accordance with the invention for detecting over- expression of FtsL protein compared to normal control tissue samples may be used to detect the presence of an infection, for example.
- Assay techniques that can be used to determine levels of a FtsL protein, in a sample de ⁇ ved from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.
- polypeptides of the invention or va ⁇ ants thereof, or cells expressing them can be used as an lmmunogen to produce antibodies lmmunospecific for such polypeptides
- Antibodies as used herein includes monoclonal and polyclonal antibodies, chime ⁇ c, single chain, simia zed antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab immunolglobu n expression library.
- Antibodies generated against the polypeptides of the invention can be obtained by admimstenng the polypeptides or epitope-bea ⁇ ng fragments, analogues or cells to an animal, preferably a nonhuman, using routine protocols.
- any technique known m the art that provides antibodies produced by continuous cell line cultures can be used. Examples include vanous techniques, such as those in Kohler, G. and Milstein, C, Nature 256 495-497 (1975); Kozbor et al , Immunology Today 4 72 (1983), Cole et al , pg 77- 96 in MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc (1985)
- phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-FtsL or from naive hbra ⁇ es (McCafferty, J. et al., (1990), Nature 348, 552-554; Marks, J. et al., (1992) Biotechnology 10, 779-783).
- the affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al., (1991) Nature 352, 624-628).
- each domain may be directed against a different epitope - termed 'bispecific' antibodies
- the above-descnbed antibodies may be employed to isolate or to identify clones expressing the polypeptides to punfy the polypeptides by affinity chromatography.
- antibodies against FtsL- polypeptide may be employed to treat infections, particularly bactenal infections and especially disease, such as, mfections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal infections, particularly bactenal infections and especially disease, such as, mfections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal infections, particularly bactenal infections and especially disease, such as, mfections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis
- CNS e.g., cerebral abscess
- Polypeptide variants include antigenically, epitopically or immunologically equivalent vanants that form a particular aspect of this invention.
- antigenically equivalent denvative encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host.
- immunologically equivalent de ⁇ vative encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host.
- the polypeptide such as an antigenically or immunologically equivalent denvative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken.
- the fusion protein may provide stability to the polypeptide
- the antigen may be associated, for example by conjugation, with an immunoge c earner protein for example bovine serum albumin (BSA) or keyhole limpet haemocyan (KLH).
- BSA bovine serum albumin
- KLH keyhole limpet haemocyan
- a multiple antigenic peptide compnsmg multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve lmmunogemcity so as to obviate the use of a earner.
- the antibody or vanant thereof is modified to make it less immunogemc m the individual.
- the antibody may most preferably be "humanized", where the complimenta ⁇ ty determining reg ⁇ on(s) of the hyb ⁇ doma-de ⁇ ved antibody has been transplanted into a human monoclonal antibody , for example as described in Jones, P. et al. (1986), Nature 321, 522-525 or Tempest et al., (1991) Biotechnology 9, 266- 273.
- a polynucleotide of the invention m genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al , Hum Mol Genet 1992, 1:363, Manthorpe et al, Hum. Gene Ther. 1963-4, 419), delivery of DNA complexed with specific protein earners (Wu et al , J Biol Chem 1989-
- Polypeptides of the invention may also be used to assess the binding of small molecule substrates and hgands in, for example, cells, cell-free preparations, chemical branes, and natural product mixtures.
- substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e g , Coligan et al , Current Protocols in Immunology 1(2) Chapter s (1991)
- the invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of FtsL polypeptides or polynucleotides, particularly those compounds that are bacte ⁇ ostatic and/or bactenocidal
- the method of screening may involve high-throughput techniques.
- a synthetic reaction mix for example, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compnsmg FtsL polypeptide and a labeled substrate or ligand of such polypeptide is incubated m the absence or the presence of a candidate molecule that may be a FtsL agonist or antagonist
- the ability of the candidate molecule to agonize or antagonize the FtsL polypeptide is reflected in decreased bindmg of the labeled ligand or decreased production of product from such substrate.
- Molecules that bind gratuitously, i e , without inducing the effects of FtsL polypeptide are most likely to be good antagonists
- Molecules that bind well and increase the rate of product production from substrate are agonists. Detection of the rate or level of production of product from substrate may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colonmet ⁇ c labeled substrate converted into product, a reporter gene that is responsive to changes in FtsL polynucleotide or polypeptide activity, and binding assays known m the art
- Another example of an assay for FtsL antagonists is a competitive assay that combines
- FtsL and a potential antagonist with FtsL-bmd g molecules, recombinant FtsL binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropnate conditions for a competitive inhibition assay FtsL can be labeled, such as by radioactivity or a
- Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity
- Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing FtsL-induced activities, thereby preventing the action of FtsL by excluding FtsL from binding
- Potential antagonists mclude a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented.
- small molecules include but are not limited to small organic molecules, peptides or peptide- ke molecules.
- Other potential antagonists mclude antisense molecules (see Okano, J Neurochem 56. 560 (1991), OUGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton, FL ( 1988), for a descnption of these molecules)
- Preferred potential antagonists include compounds related to and va ⁇ ants of FtsL
- Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds.
- the encoded protein upon expression, can be used as a target for the screening of antibacterial drugs Additionally, the DNA sequences encoding the ammo terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.
- the invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection.
- the molecules of the invention may be used: in the prevention of adhesion of bactena, in particular gram positive bacteria, to mammalian extracellular mat ⁇ x proteins on m-dwelling devices or to extracellular mat ⁇ x proteins in wounds, to block FtsL protem-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kmases (Rosenshine et al , Infect Immun 60 221 1 (1992), to block bacterial adhesion between mammalian extracellular mat ⁇ x
- the antagonists and agonists of the invention may be employed, for instance, to inhibit and treat disease, such as, infections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e g , empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory diarrhoea, splenic absces, retropentoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepha ⁇ tis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital celluhtis, darcryocystitis), kidney and u ⁇ nary tract (e.g., epididymitis, mtrarenal and pe ⁇ neph ⁇ c absces, toxic shock syndrome), skm (e.g
- H pylori Helicobacter pylori bacteria infect the stomachs of over one-third of the world's population causing stomach cancer, ulcers, and gast ⁇ tis
- International Agency for Research on Cancer (1994) Schistosomes, Liver Flukes and Helicobacter Pylon International Agency for Research on Cancer, Lyon, France; http://www.uicc.ch/ecp/ecp2904.htm).
- the international Agency for Research on Cancer recently recognized a cause-and- effect relationship between H. pylori and gast ⁇ c adenocarcmoma, classifying the bacte ⁇ um as a Group I (definite) carcinogen.
- Preferred antimicrobial compounds of the invention (agonists and antagonists of FtsL) found using screens provided by the invention, particularly broad- spectrum antibiotics, should be useful in the treatment of H. pylori infection Such treatment should decrease the advent of H. cancers, such as gastrointestinal carcinoma. Such treatment should also cure gast ⁇ c ulcers and gast ⁇ tis.
- Vaccines Another aspect of the invention relates to a method for inducing an immunological response m an individual, particularly a mammal which compnses inoculating the individual with FtsL, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bactenal infection and most particularly Staphylococcus aureus infection. Also provided are methods whereby such immunological response slows bactenal replication.
- Yet another aspect of the invention relates to a method of inducing immunological response in an individual which compnses dehve ⁇ ng
- nucleic acid vector to direct expression of FtsL, or a fragment or a variant thereof, for expressing FtsL, or a fragment or a variant thereof in vivo in order to induce an immunological response, such as, to produce antibody and or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not.
- an immunological response such as, to produce antibody and or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not.
- One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise.
- nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid.
- a further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, induces an immunological response in such individual to a FtsL or protein coded therefrom, wherein the composition comprises a recombinant FtsL or protein coded therefrom compnsing DNA which codes for and expresses an antigen of said FtsL or protein coded therefrom.
- the immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.
- a FtsL polypeptide or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties.
- fused recombinant protein preferably further comprises an antigenic co-protein, such as lipoprotein D from Hemophilus influenzae, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-protems which solubilize the protein and facilitate production and purification thereof.
- the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system.
- the co-protein may be attached to either the ammo or carboxy terminus of the first protein.
- compositions particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. et al. Science 273: 352 (1996). Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of
- the polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacte ⁇ a, for example by blocking adherence of bacteria to damaged tissue.
- tissue damage include wounds m skm or connective tissue caused, e.g., by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagma.
- the invention also includes a vaccine formulation which compnses an immunogemc recombinant protein of the invention together with a suitable earner.
- the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or mtradermal.
- Formulations suitable for parenteral administration include aqueous and non-aqueous stenle injection solutions which may contain anti-oxidants, buffers, bactenostats and solutes which render the formulation lnsoto c with the bodily fluid, preferably the blood, of the individual, and aqueous and non-aqueous ste ⁇ le suspensions which may include suspending agents or thickening agents
- the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-d ⁇ ed condition requinng only the addition of the stenle liquid earner immediately pnor to use.
- the vaccine formulation may also include adjuvant systems for enhancing the lmmunogenicity of the formulation, such as oil-in water systems and other systems known in the
- compositions for purposes of compositions, kits and administration
- the invention also relates to compositions compnsmg the polynucleotide or the polypeptides discussed above or their agonists or antagonists
- the polypeptides of the invention may be employed m combination with a non-ste ⁇ le or ste ⁇ le earner or earners for use with cells, tissues or organisms, such as a pharmaceutical earner suitable for administration to a subject.
- Such compositions compnse for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable earner or excipient
- Such earners may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof.
- the formulation should suit the mode of administration
- the invention further relates to diagnostic and pharmaceutical packs and kits compnsmg one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention
- Polypeptides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.
- compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intrapentoneal, intramuscular, subcutaneous, mtranasal or mtradermal routes among others
- the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isoto c
- the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropnate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams.
- Such topical formulations may also contain compatible conventional earners, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions.
- Such earners may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation
- the daily dosage level of the active agent will be from 0 01 mg kg to 10 mg/kg, typically around 1 mg/kg.
- the physician m any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual.
- the above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are mented, and such are within the scope of this invention.
- In-dwelling devices include surgical implants, prosthetic devices and catheters, i.e., devices that are introduced to the body of an individual and remain in position for an extended time.
- Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrosp al fluid shunts, unnary catheters, continuous ambulatory pentoneal dialysis (CAPD) catheters.
- CAPD continuous ambulatory pentoneal dialysis
- composition of the invention may be administered by injection to achieve a systemic effect against relevant bacte ⁇ a shortly before insertion of an in-dwelling device. Treatment may be continued after surgery during the m-body time of the device.
- the composition could also be used to broaden pe ⁇ operative cover for any surgical technique to prevent bactenal wound infections, especially Staphylococcus aureus wound infections.
- compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bactena to matnx proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.
- the composition of the invention may be used to bathe an indwelling device immediately before insertion.
- the active agent will preferably be present at a concentration of l ⁇ g/ml to lOmg/ml for bathing of wounds or indwelling devices
- a vaccine composition is conveniently in mjectable form. Conventional adjuvants may be employed to enhance the immune response
- a suitable unit dose for vaccination is 0 5-5 microgram kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.
- Example 1 Strain selection, Library Production and Sequencing The polynucleotide having the DNA sequence given in SEQ ED NO: l was obtained from a library of clones of chromosomal DNA of Staphylococcus aureus in E. coli. The sequencing data from two or more clones containing overlapping Staphylococcus aureus DNAs was used to construct the contiguous DNA sequence in SEQ ID NO: l. Libraries may be prepared by routine methods, for example: Methods 1 and 2 below.
- Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures.
- DNA fragments of up to 1 lkbp in size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added. Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E.coli infected with the packaged library.
- the library is amplified by standard procedures.
- Total cellular DNA is partially hydrolyzed with a one or a combination of rest ⁇ ction enzymes appropnate to generate a series of fragments for cloning into library vectors (e.g., Rsal, Pall, Alul, Bshl235I), and such fragments are size-fractionated according to standard procedures.
- library vectors e.g., Rsal, Pall, Alul, Bshl235I
- EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E.coli infected with the packaged library.
- the library is amplified by standard procedures.
- ADDRESSEE Dechert Price & Rhoads
Abstract
The invention provides FtsL polypeptides and DNA (RNA) encoding FtsL polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing FtsL polypeptides to screen for antibacterial compounds.
Description
NOVEL FtsL
RELATED APPLICATIONS
This application claims benefit of GB application number 9616312.6, filed August 2,
1996 and U.S. Provisional Application Serial Number 60/027,301, filed October 1, 1996.
FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, in these and in other regards, the invention relates to novel polynucleondes and polypeptides of the penicillin binding protein family, hereinafter referred to as "FtsL".
BACKGROUND OF THE INVENTION
It is particularly preferred to employ Staphylococcal genes and gene products as targets for the development of antibiotics. The Staphylococci make up a medically important genera of microbes. T ey are known to produce two types of disease, invasive and toxigenic. Invasive infections are characteπzed generally by abscess formation effecting both skin surfaces and deep tissues. S. aureus is the second leading cause of bacteremia in cancer patients Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacteπal endocarditis are also relatively common. There are at least three clinical conditions resulting from the toxigenic properties of Staphylococci. The manifestation of these diseases result from the actions of exotoxms as opposed to tissue invasion and bacteremia. These conditions include: Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome
The frequency of Staphylococcus aureus infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate Staphylococcus aureus strains which are resistant to some or all of the standard antibiotics.
This has created a demand for both new anti-microbial agents and diagnostic tests for this organism.
FtsL is a membrane bound protein involved in bactenal cell division. FtsL is essential for cell growth and division. An ftsL null mutation results in inhibition of cell division, the formation of long, non-septate filaments, and ultimately cessation of growth and lysis (Guzman, L-M., Barondess, J. J., and Beckwith, J. (1992) J. Bacteπol 174 : 7716-7728)
In Escheπchia coh the ftsL gene is located immediately upstream of ftsl which codes for
Penicilhn-bmdmg protein 3, a membrane protein specifically required during septation (Ishmo, F.,
& Matsuhashi, M. (1981) Biochem. Biophys. Res. Commun. 101 : 905-911). FtsL is also a cytoplasmic membrane protein with a cytoplasmic N-terminus, a membrane-spanning segment, and a penplasmic carboxy terminus.
Although there are many examples of cell division proteins in E.coli their precise functions are mostly unknown. However it is likely that membrane proteins involved in cell division will have a major role in the regulation of cell division and in septum initiation. FtsL homologues have been reported in Haemophilus lnfiuenzae (Fleischmann, R. et al
(1995) Science 269 • 496-512) and Bacillus subti s (Daniel, R A., Williams, A. M., Erπngton, J. (1995) Genbank Accession Z68230).
Clearly, there is a need for factors, such as the novel compounds of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity. Such factors are also useful to determine their role m pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists which can play a role in preventing, ameliorating or correcting infections, dysfunctions or diseases.
The polypeptides of the invention have amino acid sequence homology to a known Bacillus subtihs FtsL protein.
SUMMARY OF THE INVENTION
It is an object of the invention to provide polypeptides that have been identified as novel FtsL polypeptides by homology between the ammo acid sequence set out in Table 1 [SEQ LD NO.
z
2] and a known ammo acid sequence or sequences of other proteins such as Bacillus subtihs FtsL protein
It is a further object of the invention to provide polynucleotides that encode FtsL polypepndes, particularly polynucleotides that encode the polypeptide herein designated FtsL In a particularly preferred embodiment of the invention the polynucleotide compπses a region encodmg FtsL polypeptides comprising the sequence set out in Table 1 [SEQ LD NO 1] which includes a full length gene, or a vanant thereof.
In another particularly preferred embodiment of the invention there is a novel FtsL protein from Staphylococcus aureus comprising the amino acid sequence of Table 1 [SEQ ID NO.2], or a vanant thereof
In accordance with another aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Staphylococcus aureus WCUH 29 strain contained in the deposited strain
A further aspect of the invention there are provided isolated nucleic acid molecules encoding FtsL, particularly Staphylococcus aureus FtsL, including mRNAs, cDNAs, genomic
DNAs Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful vaπants thereof, and compositions compπsmg the same.
In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization Among the particularly preferred embodiments of the invention are naturally occurring allehc vanants of FtsL and polypeptides encoded thereby
Another aspect of the invention there are provided novel polypeptides of Staphylococcus aureus referred to herein as FtsL as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful vanants thereof, and composmons compπsing the same
Among the particularly preferred embodiments of the invention are vaπants of FtsL polypeptide encoded by naturally occurring alleles of the FtsL gene.
In a preferred embodiment of the invention there are provided methods for producing the aforementioned FtsL polypeptides. In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibactenal agents, including, for example, antibodies
In accordance with certain preferred embodiments of the invention, there are provided products, compositions and methods for assessing FtsL expression, treating disease, for example, disease, such as, infections of the upper respiratory tract (e g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g , infective endocarditis), gastrointestinal (e.g , secretory diarrhoea, splenic absces, retropeπtoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blephaπtis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellu tis, darcryocyshtis), kidney and unnary tract (e.g., epididymitis, intrarenal and peπnephπc absces, toxic shock syndrome), skin (e.g., impetigo, follicu tis, cutaneous abscesses, celluhtis, wound infection, bactenal myositis) bone and joint (e.g., septic arthπtis, osteomyelitis), assaying genetic vaπation, and admmisteπng a FtsL polypeptide or polynucleotide to an organism to raise an lmmunological response against a bacteπa, especially a Staphylococcus aureus bactena
In accordance with certain preferred embodiments of this and other aspects of the invention there are provided polynucleotides that hybπdize to FtsL polynucleotide sequences, particularly under stnngent conditions.
In certain preferred embodiments of the invention there are provided antibodies against FtsL polypeptides.
In other embodiments of the invention there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention compπsmg: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal m response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determinmg whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polynucleotide.
In accordance with yet another aspect of the invention, there are provided FtsL agonists and antagonists, preferably bacteπostatic or bacteπocidal agonists and antagonists.
In a further aspect of the invention there are provided compositions compnsing a FtsL polynucleotide or a FtsL polypeptide for administration to a cell or to a multicellular organism
Vaπous changes and modifications within the spiπt and scope of the disclosed invention will become readily apparent to those skilled m the art from reading the following descπptions and from reading the other parts of the present disclosure.
GLOSSARY
The following definitions are provided to facilitate understanding of certain terms used frequently herein
"Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.
"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between stnngs of such sequences. "Identity" and "similaπty" can be readily calculated by known methods, including but not limited to those descπbed m (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988, Biocomputing Informatics and Genome Projects, Smith, D W , ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer. Gπbskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM / Applied Math , 48 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similaπty are codified m publicly available computer programs Preferred computer program methods to determine identity and similanty between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., J. Molec. Biol. 215. 403-410 (1990). The BLAST X program is publicly available from NCBI and other sources {BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD
20894, Altschul, S , et al , J Mol Biol 215 403-410 (1990) As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides m the reference sequence may be inserted into the reference sequence These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides m the reference sequence or in one or more contiguous groups within the reference sequence. Analogously , by a polypeptide having an ammo acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO 2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ LD NO 2 In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference ammo acid sequence, up to 5% of the ammo acid residues in the reference sequence may be deleted or substituted with another ammo acid, or a number of amino acids up to 5% of the total ammo acid residues m the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference ammo acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or m one or more contiguous groups within the reference sequence
"Isolated" means altered "by the hand of man" from its natural state, i e , if it occurs m nature, it has been changed or removed from its oπginal environment, or both. For example, a polynucleonde or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting mateπals of its natural state is "isolated" as the term is employed herein
&
"Polynucleotιde(s)" generally refers to any polyπbonucleotide or polydeoxπbonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotιde(s)" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and tnple-stranded regions, single- and double- stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybnd molecules compnsmg DNA and RNA that may be single-stranded or, more typically, double-stranded, or tnple-stranded regions, or a mixture of single- and double-stranded regions. In addition, "polynucleotide" as used herein refers to tnple-stranded regions compπsmg RNA or DNA or both RNA and DNA. The strands m such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a tπple-helical region often is an ohgonucleotide. As used herein, the term "polynucleotιde(s)" also includes DNAs or RNAs as descnbed above that contain one or more modified bases Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotιde(s)" as that term is intended herein Moreover, DNAs or RNAs compnsmg unusual bases, such as inosine, or modified bases, such as tπtylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great vanety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term "polynucleotιde(s)" as it is employed herein embraces such chemically, enzymatically or metabolicaily modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteπstic of viruses and cells, including, for example, simple and complex cells. "Polynucleotιde(s)" also embraces short polynucleotides often referred to as ohgonucleotιde(s).
"Polypeptιde(s)" refers to any peptide or protein compnsmg two or more ammo acids joined to each other by peptide bonds or modified peptide bonds. "Polypeptιde(s)" refers to both short chains, commonly referred to as peptides, o gopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain ammo acids other than the 20 gene encoded amino acids. "Polypeptιde(s)" include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques. Such modifications are well descnbed in basic texts and in more detailed monographs, as well as in a volummous research literature, and they are well known to those of skill in the art. It will be appreciated that the same type of modification may be present in the
same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Modifications can occur anywhere m a polypeptide, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini. Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide deπvative, covalent attachment of a lipid or lipid deπvative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, lodination, methylation, mynstoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-πbosylation, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins, such as arginylation, and ubiquitination. See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993) and Wold, F., Posttranslational Protein Modifications: Perspecnves and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York (1983); Seifter et al., Meth Enzymol. 182:626-646 (1990) and Rattan et al., Protein Synthesis: Posttranslational Modifications and Aging, Ann. N.Y. Acad. Sci. 663: 48-62 (1992). Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.
"Variant(s)" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential propeπies. A typical vanant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the vanant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in ammo acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are
closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occumng such as an allelic variant, or it may be a variant that is not known to occur naturally. Non- naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.
DESCRIPTION OF THE INVENTION
The invention relates to novel FtsL polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a novel FtsL of Staphylococcus aureus, which is related by ammo acid sequence homology to Bacillus subtilis FtsL polypeptide. The invention relates especially to FtsL having the nucleotide and ammo acid sequences set out in Table 1 [SEQ LD NO: 1] and Table 1 [SEQ ID NO: 2] respectively, and to the FtsL nucleotide sequences of the DNA in the deposited strain and amino acid sequences encoded thereby.
TABLE 1 FtsL Polynucleotide and Polypeptide Sequences
(A) Sequences from Staphylococcus aureus FtsL polynucleotide sequence [SEQ ID NO: 1 ] .
5 ' - 1 ATGGCTGTAG AAAAAGTGTA CCAACCATAT GACGAACAAG TTTATAATAG
51 TATACCGAAG CAACAACCAC AAACTAAGCC CGAAAAGAAG ACTGTTTCGA
101 GAAAAGTGGT TGTACAATTA ACTAAATTTG AAAAAGTTTT ATACATAACT
151 TTGATTACTG TAATTGCTAT GTTAAGTATT TATATGCTAT CTTTAAAAAT
201 GGATGCGTAT GATACGCGAG GAAAGATTGC AGATTTAGAT TATAAAATAG
°l
251 ATAAACAATC AAGTGAAAAC AGTGCTTTAC AATCTGAAAT CAAAAAGAAT
301 TCTTCTTATG AACGCATATA CGAAAAGGCT AAGAAACAGG GGATGAGCCT
351 TGAGAACGAT AATGTAAAGG TAGTGCGTAG TAATGGCGAA GCAAAAAAT- 3 '
(B) FtsL polypeptide sequence deduced from the polynucleotide sequence in this table [SEQ ID NO:2j\
NH- - 1 MAVEKVYQPY DEQVΥNS IPK QQPQTKPEKK TVSRKWVQL TKFEKVLYIT
51 ITVIAMLSI YMLS KMDAY DTRGKIADLD YKIDKQSSEN SALQSEIKK
101 SSYERIYEKA KKQGMSLEND NVKWRSNGE AKN-COOH
(C) Polynucleotide sequence embodiments [SEQ ID NO: 1 ]. χ-(Rl)n"1 ATGGCTGTAG AAAAAGTGTA CCAACCATAT GACGAACAAG TTTATAATAG
51 TATACCGAAG CAACAACCAC AAACTAAGCC CGAAAAGAAG ACTGTTTCGA
101 GAAAAGTGGT TGTACAATTA ACTAAATTTG AAAAAGTTTT ATACATAACT
151 TTGATTACTG TAATTGCTAT GTTAAGTATT TATATGCTAT CTTTAAAAAT
201 GGATGCGTAT GATACGCGAG GAAAGATTGC AGATTTAGAT TATAAAATAG
251 ATAAACAATC AAGTGAAAAC AGTGCTTTAC AATCTGAAAT CAAAAAGAAT
301 TCTTCTTATG AACGCATATA CGAAAAGGCT AAGAAACAGG GGATGAGCCT
351 TGAGAACGAT AATGTAAAGG TAGTGCGTAG TAATGGCGAA GCAAAAAAT- (R2 ) n-
I V
(D) Polypeptide sequence embodiments [SEQ ID NO:2].
X - ( R1 ) n - l MAVEKVYQPY DEQVYNSIPK QQPQTKPEKK TVSRKVWQL TKFEKVLYIT
51 LITVIAMLSI YMLSLKMDAY DTRGKIADLD YKIDKQSSEN SALQSEIKKN
101 SSYERIYEKA KKQGMSLEND NVKWRSNGE AKN- ( R2 ) n -Y
(E) Sequences from Staphylococcus aureus FtsL polynucleotide ORF sequence [SEQ ID NO:3]. 5'-l ATGACCGANC AAGTTTATAA TAGTATACCG AAGCAACAAC CACANACTAA
51 GCCCGAAAAG AAGACTGTTT CGAGAAAAGT GGTTGTACAA TTAACTAAAT
101 TTGNAAAAGT TTTATACATA ACTTTGATTA CTGTAATTGC TATGTTAAGT
151 ATTTATATGC TATCTTTAAA AATGGATGCG TATGATACGC GAGGAAAGAT
201 TGCAGATTTA GATTATAAAA TAGATAAACA ATCAAGTGAA AACAGTGCTT
251 TACAATCTGA AATCAAAAAG AATTCTTCTT ATGAACGCAT ATACGAAAAG
301 GCTAAGAAAC AGGGGATGAG CCTTGAGAAC GATAATGTAA AGGTAGTGCG
351 TAGTAATGGC GAAGCAAAAA AT-3 '
(F) FtsL polypeptide sequence deduced from the polynucleotide ORF sequence m this table [SEQ ID NO:4].
NH2-1 MTXQVYNSIP KQQPXTKPEK KTVSRKVWQ LTKFXKVLYI TLITVIAMLS
51 IYMLSLKMDA YDTRGKIADL DYKIDKQSSE NSALQSEIKK NSSYERIYEK
101 AKKQGMSLEN DNVKWRSNG EAKN-COOH
//
Deposited materials
A deposit containing a Staphylococcus aureus WCUH 29 strain has been deposited with the National Collections of Industnal and Maπne Bacteπa Ltd. (herein "NCIMB"), 23 St Machar Dnve, Aberdeen AB2 1RY, Scotland on 11 September 1995 and assigned NCIMB Deposit No 40771, and is referred to as Staphylococcus aureus WCUH29 on deposit The Staphylococcus aureus strain deposit is referred to herein as "the deposited strain" or as "the DNA of the deposited strain."
The deposited strain contains the full length FtsL gene. The sequence of the polynucleotides contained in the deposited strain, as well as the ammo acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any descnption of sequences herein.
The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The strain will be irrevocably and without restnction or condition released to the public upon the issuance of a patent The deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112
A license may be required to make, use or sell the deposited strain, and compounds deπved therefrom, and no such license is hereby granted Polypeptides
The polypeptides of the invention include the polypeptide of Table 1 [SEQ ID NO 2] (m particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of FtsL, and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ED NOS:2 and 4] or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NOS.2 and 4], and more preferably at least 90% similaπty (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NOS.2 and 4] and still more preferably at least 95% similaπty (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ED NOS:2 and 4] and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 ammo acids and more preferably at least 50 amino acids
lλ
The invention also includes polypeptides of the formula set forth in Table 1 (D) [SEQ LD
NO:2] wherein, at the ammo terminus, X is hydrogen, and at the carboxyl terminus, Y is hydrogen or a metal, R\ and R2 is any ammo acid residue, and n is an integer between 1 and
1000. Any stretch of ammo acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.
A fragment is a vanant polypeptide having an ammo acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides As with FtsL polypeptides fragments may be "free-standing," or compπsed within a larger polypeptide of which they form a part or region, most preferably as a single continuous region, a single larger polypeptide.
Preferred fragments include, for example, truncation polypeptides having a portion of an ammo acid sequence of Table 1 [SEQ ID NOS:2 and 4], or of vaπants thereof, such as a continuous senes of residues that includes the ammo terminus, or a continuous senes of residues that includes the carboxyl terminus. Degradation forms of the polypeptides of the invention in a host cell, particularly a Staphylococcus aureus, are also preferred. Further preferred are fragments characteπzed by structural or functional attributes such as fragments that compnse alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn- forming regions, coil and coil-forming regions, hydrophi c regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.
Also preferred are biologically active fragments which are those fragments that mediate activities of FtsL, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigenic or lmmunogenic in an animal, especially in a human. Particularly preferred are fragments compnsmg receptors or domains of enzymes that confer a function essential for viability of Staphylococcus aureus or the ability to initiate, or maintain cause disease in an individual, particularly a human.
Vaπants that are fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these vanants may be employed as intermediates for producing the full-length polypeptides of the invention.
lό
Polynucleotides
Another aspect of the invention relates to isolated polynucleotides, including the full length gene, that encode the FtsL polypeptide having a deduced amino acid sequence of Table 1 [SEQ ID NOS:2 and 4] and polynucleotides closely related thereto and vaπants thereof. Using the information provided herein, such as a polynucleotide sequence set out m Table
1 [SEQ ID NOS:l and 3], a polynucleotide of the invention encoding FtsL polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteπa using Staphylococcus aureus WCUH 29 cells as starting matenal, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a sequence given in Table 1 [SEQ ID NOS. l and 3], typically a library of clones of chromosomal DNA of Staphylococcus aureus WCUH 29 in E coli or some other suitable host is probed with a radiolabeled ohgonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stnngent conditions. By sequencing the individual clones thus identified with sequencing primers designed from the ongmal sequence it is then possible to extend the sequence m both directions to determine the full gene sequence. Conveniently, such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are descnbed by Mamatis, T., Fntsch, E.F and Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, 2nd Ed., Cold Spπng Harbor Laboratory Press, Cold Spπng Harbor, New York (1989) (see in particular Screening By Hybπdization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13 70) Illustrative of the invention, the polynucleotide set out m Table 1 [SEQ ID NO 1] was discovered in a DNA library deπved from Staphylococcus aureus WCUH 29.
The DNA sequence set out m Table 1 [SEQ ED NOS:l] contains an open reading frame encoding a protein having about the number of ammo acid residues set forth in Table 1 [SEQ ID NO:2] with a deduced molecular weight that can be calculated using ammo acid residue molecular weight values well known in the art. The polynucleotide of SEQ D NO. 1, between nucleotide number 1 through number 399 encodes the polypeptide of SEQ ED NO:2
FtsL of the invention is structurally related to other proteins of the penicillin binding protein family, as shown by the results of sequencing the DNA encoding FtsL of the deposited strain. The protein exhibits greatest homology to Bacillus subtilis FtsL protein among known
π
proteins FtsL of Table 1 [SEQ ED NO 2] has about 26% identity over its entire length and about 41% similanty over its entire length with the ammo acid sequence of Bacillus subtihs FtsL polypeptide
The invention provides a polynucleotide sequence identical over its entire length to the coding sequence in Table 1 [SEQ ID NO 1] Also provided by the invention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment in reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence The polynucleotide may also contain non-coding sequences, including for example, but not limited to non-codmg 5' and 3' sequences, such as the transcnbed, non-translated sequences, termination signals, πbosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional coding sequence which encode additional ammo acids For example, a marker sequence that facilitates punfication of the fused polypeptide can be encoded In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc ) and descnbed m Gentz et al , Proc Natl Acad. Sci , USA 86 821-824 (1989), or an HA tag (Wilson et al , Cell 37 767 (1984) Polynucleotides of the invention also include, but are not limited to, polynucleotides compnsmg a structural gene and its naturally associated sequences that control gene expression
A preferred embodiment of the invention is a polynucleotide of compnsmg nucleotide 1 to 399 set forth in SEQ ED NO: 1 of Table 1 which encode the FtsL polypeptide
The invention also includes polynucleotides of the formula set forth in Table 1 (C)[SEQ ED NO 1] wherein, at the 5' end of the molecule, X is hydrogen, and at the 31 end of the molecule, Y is hydrogen or a metal, Rj and R2 is any nucleic acid residue, and n is an mteger between 1 and 1000. Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer
The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bactenal polypeptide and more particularly a polypeptide of the Staphylococcus aureus FtsL having the ammo acid sequence set out in Table 1 [SEQ ED NO.2] The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the
/->
polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain coding and/or non-coding sequences
The invention further relates to vaπants of the polynucleotides descnbed herein that encode for vanants of the polypeptide having the deduced ammo acid sequence of Table 1 [SEQ ED NO.2]. Vanants that are fragments of the polynucleotides of the invention may be used to synthesize full-length polynucleotides of the invention.
Further particularly preferred embodiments are polynucleotides encoding FtsL vanants, that have the am o acid sequence of FtsL polypeptide of Table 1 [SEQ ED NO 2] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no ammo acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of FtsL.
Further preferred embodiments of the invention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding FtsL polypeptide having an amino acid sequence set out m Table 1 [SEQ ID NOS:2 and 4], and polynucleotides that are complementary to such polynucleotides. Alternatively, most highly preferred are polynucleotides that compnse a region that is at least 80% identical over its entire length to a polynucleotide encoding FtsL polypeptide of the deposited strain and polynucleotides complementary thereto In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred
Preferred embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Table 1 [SEQ ED NO:l],
The invention further relates to polynucleotides that hybndize to the herem above- descnbed sequences. In this regard, the invention especially relates to polynucleotides that hybndize under stπngent conditions to the herein above-descnbed polynucleotides. As herein used, the terms "stπngent conditions" and "stnngent hybπdization conditions" mean hybπdization will occur only if there is at least 95% and preferably at least 97% identity between the sequences An example of stπngent hybπdization conditions is overnight incubation at 42°C in a solution
compnsmg 50% formamide, 5x SSC (150mM NaCl, 15mM tnsodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybπdization support in 0 lx SSC at about 65°C Hybndization and wash conditions are well known and exemplified in Sambrook, et al., Molecular Cloning A Laboratory Manual, Second Edition, Cold Spnng Harbor, N Y., (1989), particularly Chapter 11 therein.
The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropnate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:l or SEQ ID NO.3 under stπngent hybπdization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:l or a fragment thereof; and isolating said DNA sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and pnmers descnbed elsewhere herein.
As discussed additionally herein regarding polynucleotide assays of the invention, for instance, polynucleotides of the invention as discussed above, may be used as a hybndization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding FtsL and to isolate cDNA and genomic clones of other genes that have a high sequence similaπty to the FtsL gene Such probes generally will compnse at least 15 bases Preferably, such probes will have at least 30 bases and may have at least 50 bases. Particularly preferred probes will have at least 30 bases and will have 50 bases or less.
For example, the coding region of the FtsL gene may be isolated by screening using the DNA sequence provided in SEQ ED NO: 1 to synthesize an oligonucleotide probe. A labeled ohgonucleotide having a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybπdizes to.
The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and matenals for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to polynucleotide assays
Polynucleotides of the invention that are o gonucleotides deπved from the sequences of SEQ ID NOS: 1 and/or 2 may be used in the processes herein as descnbed, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are
n
transcnbed in bactena in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained
The invention also provides polynucleotides that may encode a polypeptide that is the mature protein plus additional ammo or carboxyl-terminal amino acids, or amino acids intenor to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role m processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things As generally is the case in vivo, the additional amino acids may be processed away from the mature protein by cellular enzymes.
A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide When prosequences are removed such inactive precursors generally are activated Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins. In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotem, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed duπng processing steps that produce active and mature forms of the polypeptide
Vectors, host cells, expression
The invention also relates to vectors that compπse a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs deπved from the DNA constructs of the invention.
For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide mto the host cell can be effected by methods descnbed in many standard laboratory manuals, such as Davis et al , BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al., MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed., Cold
t
Spnng Harbor Laboratory Press, Cold Spnng Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, catiomc lipid- mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection Representative examples of appropnate hosts include bactenal cells, such as streptococci, staphylococci, enterococci E coli, streptomyces and Bacillus subtύis cells; fungal cells, such as yeast cells and Aspergύlus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells, animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells A great vanety of expression systems can be used to produce the polypeptides of the invention Such vectors include, among others, chromosomal, episomal and virus-denved vectors, e g , vectors deπved from bactenal plasmids, from bacteπophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors deπved from combinations thereof, such as those deπved from plasmid and bacteπophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropnate DNA sequence may be inserted into the expression system by any of a vanety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, (supra).
For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the peπplasmic space or into the extracellular environment, appropnate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
Polypeptides of the invention can be recovered and puπfied from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid
t l
chromatography is employed for puπfication. Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured dunng isolation and or punfication. Diagnostic Assays This invention is also related to the use of the FtsL polynucleotides of the invention for use as diagnostic reagents. Detection of FtsL in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease. Eukaryotes (herein also "mdιvιdual(s)"), particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism compnsmg the FtsL gene may be detected at the nucleic acid level by a vanety of techniques.
Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification technique pπor to analysis. RNA or cDNA may also be used in the same ways. Using amplification, charactenzation of the species and strain of prokaryote present in an individual, may be made by an analysis of the genotype of the prokaryote gene. Deletions and insertions can be detected by a change in size of the amplified product m compaπson to the genotype of a reference sequence Point mutations can be identified by hybπdizing amplified DNA to labeled FtsL polynucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denatunng agents, or by direct DNA sequencing. See, e.g , Myers et al., Science, 230 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and SI protection or a chemical cleavage method. See, e.g , Cotton et al., Proc Natl. Acad. Sci., USA, 85. 4397-4401 (1985).
Cells carrying mutations or polymorphisms in the gene of the invention may also be detected at the DNA level by a vanety of techniques, to allow for serotypmg, for example. For example, RT-PCR can be used to detect mutations. It is particularly preferred to used RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA or cDNA
2 o
may also be used for the same purpose, PCR or RT-PCR. As an example, PCR pnmers complementary to a nucleic acid encoding FtsL can be used to identify and analyze mutations.
The invention further provides these pnmers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These pnmers may be used for, among other things, amplifying FtsL DNA isolated from a sample derived from an individual. The pnmers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to vanous techniques for elucidation of the DNA sequence. In this way, mutations m the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent. The invention further provides a process for diagnosing, disease, preferably bactenal infections, more preferably infections by Staphylococcus aureus, and most preferably disease, such as, infections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory diarrhoea, splenic absces, retropentoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital celluhtis, darcryocystitis), kidney and urinary tract (e.g., epididymitis, intrarenal and pennephπc absces, toxic shock syndrome), skm (e.g., impetigo, folhculitis, cutaneous abscesses, celluhtis, wound infection, bactenal myositis) bone and joint (e.g., septic arthritis, osteomyelitis), comprising determinmg from a sample derived from an individual a increased level of expression of polynucleotide having the sequence of Table 1 [SEQ ID NO: 1]. Increased or decreased expression of FtsL polynucleotide can be measured using any on of the methods well known in the art for the quantation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybπdization methods. In addition, a diagnostic assay in accordance with the invention for detecting over- expression of FtsL protein compared to normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of a FtsL protein, in a sample deπved from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.
Antibodies
The polypeptides of the invention or vaπants thereof, or cells expressing them can be used as an lmmunogen to produce antibodies lmmunospecific for such polypeptides
"Antibodies" as used herein includes monoclonal and polyclonal antibodies, chimeπc, single chain, simia zed antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab immunolglobu n expression library.
Antibodies generated against the polypeptides of the invention can be obtained by admimstenng the polypeptides or epitope-beaπng fragments, analogues or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique known m the art that provides antibodies produced by continuous cell line cultures can be used. Examples include vanous techniques, such as those in Kohler, G. and Milstein, C, Nature 256 495-497 (1975); Kozbor et al , Immunology Today 4 72 (1983), Cole et al , pg 77- 96 in MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc (1985)
Techniques for the production of single chain antibodies (U.S Patent No 4,946.778) can be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies.
Alternatively phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-FtsL or from naive hbraπes (McCafferty, J. et al., (1990), Nature 348, 552-554; Marks, J. et al., (1992) Biotechnology 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al., (1991) Nature 352, 624-628).
If two antigen binding domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies The above-descnbed antibodies may be employed to isolate or to identify clones expressing the polypeptides to punfy the polypeptides by affinity chromatography.
Thus, among others, antibodies against FtsL- polypeptide may be employed to treat infections, particularly bactenal infections and especially disease, such as, mfections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal
(e.g., secretory diarrhoea, splenic absces, retropentoneal abscess), CNS (e.g., cerebral abscess),
lλ
eye (e.g., blephantis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital celluhtis, darcryocystitis), kidney and unnary tract (e.g., epididymitis, lntrarenal and peπnephnc absces, toxic shock syndrome), skin (e.g., impetigo, folhcu tis, cutaneous abscesses, celluhtis, wound infection, bactenal myositis) bone and joint (e g., septic arthntis, osteomyelitis) Polypeptide variants include antigenically, epitopically or immunologically equivalent vanants that form a particular aspect of this invention. The term "antigenically equivalent denvative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host. The term "immunologically equivalent deπvative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host.
The polypeptide, such as an antigenically or immunologically equivalent denvative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability to the polypeptide The antigen may be associated, for example by conjugation, with an immunoge c earner protein for example bovine serum albumin (BSA) or keyhole limpet haemocyan (KLH). Alternatively a multiple antigenic peptide compnsmg multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve lmmunogemcity so as to obviate the use of a earner.
Preferably, the antibody or vanant thereof is modified to make it less immunogemc m the individual. For example, if the individual is human the antibody may most preferably be "humanized", where the complimentaπty determining regιon(s) of the hybπdoma-deπved antibody has been transplanted into a human monoclonal antibody , for example as described in Jones, P. et al. (1986), Nature 321, 522-525 or Tempest et al., (1991) Biotechnology 9, 266- 273.
The use of a polynucleotide of the invention m genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al , Hum Mol Genet 1992, 1:363, Manthorpe et al, Hum. Gene Ther. 1963-4, 419), delivery of DNA complexed with specific protein earners (Wu et al , J Biol Chem 1989-
ϊ
264,16985), coprecφitation of DNA with calcium phosphate (Benvemsty & Reshef. PNAS USA, 1986:83,9551), encapsulation of DNA in various forms of posomes (Kaneda et al , Science 1989:243,375), particle bombardment (Tang et al , Nature 1992, 356: 152, Eisenbraun et al , DNA Cell Biol 1993, 12.791) and in vivo infection using cloned retroviral vectors (Seeger et al., PNAS USA 1984 81 ,5849)
Antagonists and agonists - assays and molecules
Polypeptides of the invention may also be used to assess the binding of small molecule substrates and hgands in, for example, cells, cell-free preparations, chemical branes, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e g , Coligan et al , Current Protocols in Immunology 1(2) Chapter s (1991)
The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of FtsL polypeptides or polynucleotides, particularly those compounds that are bacteπostatic and/or bactenocidal The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagoists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compnsmg FtsL polypeptide and a labeled substrate or ligand of such polypeptide is incubated m the absence or the presence of a candidate molecule that may be a FtsL agonist or antagonist The ability of the candidate molecule to agonize or antagonize the FtsL polypeptide is reflected in decreased bindmg of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously, i e , without inducing the effects of FtsL polypeptide are most likely to be good antagonists Molecules that bind well and increase the rate of product production from substrate are agonists. Detection of the rate or level of production of product from substrate may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colonmetπc labeled substrate converted into product, a reporter gene that is responsive to changes in FtsL polynucleotide or polypeptide activity, and binding assays known m the art
Another example of an assay for FtsL antagonists is a competitive assay that combines
FtsL and a potential antagonist with FtsL-bmd g molecules, recombinant FtsL binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropnate conditions for a competitive inhibition assay FtsL can be labeled, such as by radioactivity or a
d Y
colonmetπc compound, such that the number of FtsL molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist
Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing FtsL-induced activities, thereby preventing the action of FtsL by excluding FtsL from binding Potential antagonists mclude a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide- ke molecules. Other potential antagonists mclude antisense molecules (see Okano, J Neurochem 56. 560 (1991), OUGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton, FL ( 1988), for a descnption of these molecules) Preferred potential antagonists include compounds related to and vaπants of FtsL
Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs Additionally, the DNA sequences encoding the ammo terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.
The invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection. In particular the molecules of the invention may be used: in the prevention of adhesion of bactena, in particular gram positive bacteria, to mammalian extracellular matπx proteins on m-dwelling devices or to extracellular matπx proteins in wounds, to block FtsL protem-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kmases (Rosenshine et al , Infect Immun 60 221 1 (1992), to block bacterial adhesion between mammalian extracellular matπx
' O
proteins and bactenal FtsL proteins that mediate tissue damage and; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.
The antagonists and agonists of the invention may be employed, for instance, to inhibit and treat disease, such as, infections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e g , empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory diarrhoea, splenic absces, retropentoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blephaπtis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital celluhtis, darcryocystitis), kidney and uπnary tract (e.g., epididymitis, mtrarenal and peπnephπc absces, toxic shock syndrome), skm (e.g., impetigo, follicu tis, cutaneous abscesses, celluhtis, wound infection, bactenal myositis) bone and joint (e.g., septic arthπtis, osteomyelitis).
Helicobacter pylori (herein H pylori) bacteria infect the stomachs of over one-third of the world's population causing stomach cancer, ulcers, and gastπtis (International Agency for Research on Cancer (1994) Schistosomes, Liver Flukes and Helicobacter Pylon (International Agency for Research on Cancer, Lyon, France; http://www.uicc.ch/ecp/ecp2904.htm). Moreover, the international Agency for Research on Cancer recently recognized a cause-and- effect relationship between H. pylori and gastπc adenocarcmoma, classifying the bacteπum as a Group I (definite) carcinogen. Preferred antimicrobial compounds of the invention (agonists and antagonists of FtsL) found using screens provided by the invention, particularly broad- spectrum antibiotics, should be useful in the treatment of H. pylori infection Such treatment should decrease the advent of H.
cancers, such as gastrointestinal carcinoma. Such treatment should also cure gastπc ulcers and gastπtis. Vaccines Another aspect of the invention relates to a method for inducing an immunological response m an individual, particularly a mammal which compnses inoculating the individual with FtsL, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bactenal infection and most particularly Staphylococcus aureus infection. Also provided are methods whereby such immunological response slows bactenal replication. Yet another aspect of the invention relates to a method of inducing immunological response in an individual which compnses dehveπng
øt &
to such individual a nucleic acid vector to direct expression of FtsL, or a fragment or a variant thereof, for expressing FtsL, or a fragment or a variant thereof in vivo in order to induce an immunological response, such as, to produce antibody and or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not. One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid.
A further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, induces an immunological response in such individual to a FtsL or protein coded therefrom, wherein the composition comprises a recombinant FtsL or protein coded therefrom compnsing DNA which codes for and expresses an antigen of said FtsL or protein coded therefrom. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.
A FtsL polypeptide or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as lipoprotein D from Hemophilus influenzae, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-protems which solubilize the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the ammo or carboxy terminus of the first protein.
Provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. et al. Science 273: 352 (1996). Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of
-
bacterial cell surface proteins m DNA constructs used in such genetic immunization expeπments m animal models of infection with Staphylococcus aureus will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or cleanng infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly Staphylococcus aureus infection, in mammals, particularly humans.
The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteπa, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds m skm or connective tissue caused, e.g., by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagma. The invention also includes a vaccine formulation which compnses an immunogemc recombinant protein of the invention together with a suitable earner. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or mtradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous stenle injection solutions which may contain anti-oxidants, buffers, bactenostats and solutes which render the formulation lnsoto c with the bodily fluid, preferably the blood, of the individual, and aqueous and non-aqueous steπle suspensions which may include suspending agents or thickening agents The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dπed condition requinng only the addition of the stenle liquid earner immediately pnor to use. The vaccine formulation may also include adjuvant systems for enhancing the lmmunogenicity of the formulation, such as oil-in water systems and other systems known in the art The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation
While the invention has been descnbed with reference to certain FtsL protein, it is to be understood that this covers fragments of the naturally occurnng protein and similar proteins
1 3*
with additions, deletions or substitutions which do not substantially affect the immunogemc properties of the recombinant protein
Compositions, kits and administration
The invention also relates to compositions compnsmg the polynucleotide or the polypeptides discussed above or their agonists or antagonists The polypeptides of the invention may be employed m combination with a non-steπle or steπle earner or earners for use with cells, tissues or organisms, such as a pharmaceutical earner suitable for administration to a subject. Such compositions compnse, for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable earner or excipient Such earners may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration The invention further relates to diagnostic and pharmaceutical packs and kits compnsmg one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention Polypeptides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.
The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intrapentoneal, intramuscular, subcutaneous, mtranasal or mtradermal routes among others In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isoto c
Alternatively the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropnate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional earners, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such earners may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation
λ-1
For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0 01 mg kg to 10 mg/kg, typically around 1 mg/kg. The physician m any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are mented, and such are within the scope of this invention.
In-dwelling devices include surgical implants, prosthetic devices and catheters, i.e., devices that are introduced to the body of an individual and remain in position for an extended time. Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrosp al fluid shunts, unnary catheters, continuous ambulatory pentoneal dialysis (CAPD) catheters.
The composition of the invention may be administered by injection to achieve a systemic effect against relevant bacteπa shortly before insertion of an in-dwelling device. Treatment may be continued after surgery during the m-body time of the device. In addition, the composition could also be used to broaden peπoperative cover for any surgical technique to prevent bactenal wound infections, especially Staphylococcus aureus wound infections.
Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia. Late deep infection is a senous comphcation sometimes leading to loss of the prosthetic joint and is accompanied by significant morbidity and mortality. It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation
In addition to the therapy descnbed above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bactena to matnx proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.
Alternatively, the composition of the invention may be used to bathe an indwelling device immediately before insertion. The active agent will preferably be present at a concentration of lμg/ml to lOmg/ml for bathing of wounds or indwelling devices A vaccine composition is conveniently in mjectable form. Conventional adjuvants may be employed to enhance the immune response A suitable unit dose for vaccination is 0 5-5
microgram kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.
Each reference disclosed herein is incorporated by reference herein in its entirety. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety.
EXAMPLES
The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.
Example 1 Strain selection, Library Production and Sequencing The polynucleotide having the DNA sequence given in SEQ ED NO: l was obtained from a library of clones of chromosomal DNA of Staphylococcus aureus in E. coli. The sequencing data from two or more clones containing overlapping Staphylococcus aureus DNAs was used to construct the contiguous DNA sequence in SEQ ID NO: l. Libraries may be prepared by routine methods, for example: Methods 1 and 2 below.
Total cellular DNA is isolated from Staphylococcus aureus WCUH 29 according to standard procedures and size-fractionated by either of two methods. Method 1
Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures. DNA fragments of up to 1 lkbp in size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added. Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E.coli infected with the packaged library. The library is amplified by standard procedures.
3 /
Method 2
Total cellular DNA is partially hydrolyzed with a one or a combination of restπction enzymes appropnate to generate a series of fragments for cloning into library vectors (e.g., Rsal, Pall, Alul, Bshl235I), and such fragments are size-fractionated according to standard procedures. EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E.coli infected with the packaged library. The library is amplified by standard procedures.
3λ
SEQUENCE LISTING (1) GENERAL INFORMATION (i) APPLICANT: SmithKline Beecham Corp. (ii) TITLE OF THE INVENTION: NOVEL FtsL
(iϋ) NUMBER OF SEQUENCES: 4
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Dechert Price & Rhoads
(B) STREET: 997 Lenox Drive, BuUding 3, Suite 210
(C) CTTY: LawrenceviUe
(D) STATE: NJ
(E) COUNTRY: USA
(F) ZIP: 08543
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: D3M Compatible ( OPERATING SYSTEM: DOS
CD) SOFTWARE: FastSEQ for Windows Version 2.0
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Bloom, Allen
(B) REGISTRATION NUMBER: 29,135
( REFERENCE/DOCKET NUMBER: GM10060
(ix) TELECOMMUNICATION INFORMATION:
21
(A) TELEPHONE: 609-520-3214
(B) TELEFAX: 609-520-3259
(C) TELEX:
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 399 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:
ATGGCTGTAG AAAAAGTGTA CCAACCATAT GACGAACAAG TTTATAATAG TATACCGAAG 60
CAACAACCAC AAACTAAGCC CGAAAAGAAG ACTGTTTCGA GAAAAGTGGT TGTACAATTA 120
ACTAAATTTG AAAAAGTTTT ATACATAACT TTGATTACTG TAATTGCTAT GTTAAGTATT 180
TATATGCTAT CTTTAAAAAT GGATGCGTAT GATACGCGAG GAAAGATTGC AGATTTAGAT 240
TATAAAATAG ATAAACAATC AAGTGAAAAC AGTGCTTTAC AATCTGAAAT CAAAAAGAAT 300
TCTTCTTATG AACGCATATA CGAAAAGGCT AAGAAACAGG GGATGAGCCT TGAGAACGAT 360
AATGTAAAGG TAGTGCGTAG TAATGGCGAA GCAAAAAAT 399
(2) INFORMATION FOR SEQ H) NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 135 amino acids
(B) TYPE: amino acid
(O STRANDEDNESS: single (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Met Ala Val Glu Lys Val Tyr Gin Pro Tyr Asp Glu Gin Val Tyr Asn 1 5 10 15
3 V
Ser He Pro Lys Gin Gin Pro Gin Thr Lys Pro Glu Lys Lys Thr Val
20 25 30
Ser Arg Lys Val Val Val Gin Leu Thr Lys Phe Glu Lys Val Leu Tyr
35 40 45
He Thr Leu He Thr Val He Ala Met Leu Ser De Tyr Met Leu Ser
50 55 60
Leu Lys Met Asp Ala Tyr Asp Thr Arg Gly Lys Be Ala Asp Leu Asp 65 70 75 80
Tyr Lys Be Asp Lys Gin Ser Ser Glu Asn Ser Ala Leu Gin Ser Glu
85 90 95
Be Lys Lys Asn Ser Ser Tyr Glu Arg Be Tyr Glu Lys Ala Lys Lys
100 105 110
Gin Gly Met Ser Leu Glu Asn Asp Asn Val Lys Val Val Arg Ser Asn
115 120 125
Gly Glu Ala Lys Asn 130
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 372 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRD7TION: SEQ ID NO:3:
ATGACCGANC AAGTTTATAA TAGTATACCG AAGCAACAAC CACANACTAA GCCCGAAAAG 60
AAGACTGTTT CGAGAAAAGT GGTTGTACAA TTAACTAAAT TTGNAAAAGT TTTATACATA 120
ACTTTGATTA CTGTAATTGC TATGTTAAGT ATTTATATGC TATCTTTAAA AATGGATGCG 180
TATGATACGC GAGGAAAGAT TGCAGATTTA GATTATAAAA TAGATAAACA ATCAAGTGAA 240
AACAGTGCTT TACAATCTGA AATCAAAAAG AATTCTTCTT ATGAACGCAT ATACGAAAAG 300
GCTAAGAAAC AGGGGATGAG CCTTGAGAAC GATAATGTAA AGGTAGTGCG TAGTAATGGC 360 GAAGCAAAAA AT 372
(2) INFORMATION FOR SEQ H) NO:4:
/3
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 124 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Met Thr Xaa Gin Val Tyr Asn Ser Be Pro Lys Gin Gin Pro Xaa Thr 1 5 10 15
Lys Pro Glu Lys Lys Thr Val Ser Arg Lys Val Val Val Gin Leu Thr
20 25 30
Lys Phe Xaa Lys Val Leu Tyr Be Thr Leu Be Thr Val Be Ala Met
35 40 45
Leu Ser Be Tyr Met Leu Ser Leu Lys Met Asp Ala Tyr Asp Thr Arg
50 55 60
Gly Lys Be Ala Asp Leu Asp Tyr Lys Be Asp Lys Gin Ser Ser Glu 65 70 75 80
Asn Ser Ala Leu Gin Ser Glu Be Lys Lys Asn Ser Ser Tyr Glu Arg
85 90 95
Be Tyr Glu Lys Ala Lys Lys Gin Gly Met Ser Leu Glu Asn Asp Asn
100 105 110
Val Lys Val Val Arg Ser Asn Gly Glu Ala Lys Asn 115 120
3
Claims
What is claimed is:
1 An isolated polynucleotide compnsmg a polynucleotide sequence selected from the group consisting of
(a) a polynucleotide having at least a 70% identity to a polynucleotide encoding a polypeptide compnsmg the amino acid sequence of SEQ ID NO.2;
(b) a polynucleotide having at least a 70% identity to a polynucleotide encoding die same mature polypeptide expressed by the FtsL gene contamed the Staphylococcus aureus of the deposited strain,
(c) a polynucleotide encoding a polypeptide compnsmg an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ED NO:2;
(d) a polynucleotide which is complementary to the polynucleotide of (a), (b) or (c); and
(e) a polynucleotide compnsmg at least 15 sequential bases of the polynucleotide of (a), (b), (c) or (d)
2 The polynucleotide of Claim 1 wherein the polynucleotide is DNA.
3 The polynucleotide of Claim 1 wherein the polynucleotide is RNA.
4 The polynucleotide of Claim 2 compnsmg the nucleic acid sequence set forth in SEQ ED NO 1
5 The polynucleotide of Claim 2 compnsmg nucleotide 1 to 399 set forth in SEQ ED NO.l
6 The polynucleotide of Claim 2 which encodes a polypeptide compnsmg the ammo acid sequence of SEQ ID NO:2
7 A vector compnsmg the polynucleotide of Claim 1
8. A host cell compnsmg the vector of Claim 7.
9 A process for producing a polypeptide compnsmg: expressing from the host cell of Claim 8 a polypeptide encoded by said DNA.
10 A process for producing a FtsL polypeptide or fragment compnsmg cultuπng a host of claim 8 under conditions sufficient for the production of said polypeptide or fragment
11. A polypeptide compnsmg an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID NO.2.
12. A polypeptide compnsmg an ammo acid sequence as set forth in SEQ ED NO.2.
3?
13. An antibody against the polypeptide of claim 11.
14. An antagonist which inhibits the activity or expression of the polypeptide of claim 11.
15. A method for the treatment of an individual in need of FtsL polypeptide comprising: administenng to the individual a therapeutically effective amount of the polypeptide of claim 11.
16. A method for the treatment of an individual having need to inhibit FtsL polypeptide comprising: administenng to the individual a therapeutically effective amount of the antagonist of Claim 14.
17. A process for diagnosing a disease related to expression or activity of the polypeptide of claim 11 in an individual compπsing:
(a) determining a nucleic acid sequence encoding said polypeptide, and/or
(b) analyzing for the presence or amount of said polypeptide in a sample deπved from the individual.
18. A method for identifying compounds which interact with and inhibit or activate an activity of the polypeptide of claim 11 compnsmg: contacting a composition compπsing the polypeptide with the compound to be screened under conditions to permit interaction between the compound and the polypeptide to assess the interaction of a compound, such interaction being associated with a second component capable of providing a detectable signal in response to the interaction of the polypeptide with the compound; and determining whether the compound interacts with and activates or inhibits an activity of the polypeptide by detecting die presence or absence of a signal generated from the interaction of the compound with the polypeptide.
19. A method for inducing an immunological response in a mammal which compnses inoculating the mammal with FtsL polypeptide of claim 11 , or a fragment or vanant thereof, adequate to produce antibody and or T cell immune response to protect said animal from disease.
20. A method of inducing immunological response in a mammal which comprises delivenng a nucleic acid vector to direct expression of FtsL polypeptide of claim 11, or fragment or a vanant thereof, for expressing said FtsL polypeptide, or a fragment or a vanant
33 thereof in vivo m order to induce an immunological response to produce antibody and or T cell immune response to protect said animal from disease.
?> 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9616312 | 1996-08-02 | ||
GBGB9616312.6A GB9616312D0 (en) | 1996-08-02 | 1996-08-02 | Novel compounds |
US2730196P | 1996-10-01 | 1996-10-01 | |
US27301P | 1996-10-01 | ||
PCT/US1997/014492 WO1998005356A1 (en) | 1996-08-02 | 1997-08-01 | NOVEL FtsL |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0951296A1 true EP0951296A1 (en) | 1999-10-27 |
Family
ID=26309808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97937305A Withdrawn EP0951296A1 (en) | 1996-08-02 | 1997-08-01 | NOVEL FtsL |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0951296A1 (en) |
JP (1) | JP2002515748A (en) |
WO (1) | WO1998005356A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1338879C (en) * | 1985-05-13 | 1997-01-28 | Commonwealth Scientific And Industrial Research Organisation | Mastitis vaccine |
CA2063316A1 (en) * | 1991-03-19 | 1992-09-20 | Larry C. Blaszczak | Dna and amino acid sequence of penicillin binding protein 2a from staphylococcus aureus strain 27r and derivatives for use in purification thereof and assay for compounds effective against methicillin resistant organisms |
-
1997
- 1997-08-01 WO PCT/US1997/014492 patent/WO1998005356A1/en not_active Application Discontinuation
- 1997-08-01 JP JP50826798A patent/JP2002515748A/en active Pending
- 1997-08-01 EP EP97937305A patent/EP0951296A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9805356A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002515748A (en) | 2002-05-28 |
WO1998005356A1 (en) | 1998-02-12 |
WO1998005356A8 (en) | 1999-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6348584B1 (en) | Fibronectin binding protein compounds | |
EP0904280A1 (en) | STREPTOCOCCUS PNEUMONIAE ASPARTYL tRNA SYNTHETASE | |
US20020076766A1 (en) | Novel glucosaminidase | |
US6586578B1 (en) | Defl | |
EP1062225A1 (en) | REPLICATIVE HELICASE dnaB OF $i(STAPHYLOCOCCUS AUREUS) | |
US6300094B1 (en) | Polynucleotides encoding a novel ABC transporter | |
EP0913474A2 (en) | Dbpa, a helicase from Staphylococcus aureus | |
WO1998010652A1 (en) | NOVEL trpS | |
EP1024821A1 (en) | Novel prokaryotic polynucleotides, polypeptides and their uses | |
EP0913481A2 (en) | Staphylococcus aureus member of the DEAD-type ATP-dependent RNA helicases (dbpB) | |
EP0899337A2 (en) | FtsY polynucleotides and polypeptides of Stapyloccoccus aureus belonging to the signal recognition protein family | |
WO1999036508A1 (en) | Histidine kinase | |
US6126937A (en) | ClpL | |
EP0893502A2 (en) | GreA from Staphylococcus aureus | |
US6524813B1 (en) | Polynucleotide encoding spo0J1 of Staphylococcus aureus | |
US5866368A (en) | GreA | |
EP0951296A1 (en) | NOVEL FtsL | |
US6346393B1 (en) | Polynucleotides encoding a ribonuclease s | |
EP0881285A1 (en) | D-Alanine transferase | |
EP1068220A1 (en) | nrdF | |
EP0968293A1 (en) | Staphylococcus 3-dehydroquinate synthase | |
EP1009443A1 (en) | priA POLYPEPTIDES | |
WO1998041234A1 (en) | Novel compounds | |
EP1071694A1 (en) | Staphylococcus aureus spo0j2: polynucleotide and protein | |
US20020058308A1 (en) | Novel greA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990303 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE DK FR GB IT LI NL |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SMITHKLINE BEECHAM CORPORATION |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 20020204 |